Multi-client Studies and Market Research

We publish a range of syndicated research reports on major US and European healthcare issues and challenges.

These studies are fully customizable, allowing clients to validate and modify interview guidelines to accommodate specific business needs. They are enhanced by our healthcare and pharmaceutical team of experts and resources, providing a solid basis for analysis and forecasts.

Our latest studies:

• The New REAlity of Relative Effectiveness: An International Comparison of Evolving Requirements (Available 2012)
• A 2011 Survey of the European Hospital Drug Market
• Payer - Industry Partnerships: Best Practices for Successful Market Access of New Pharmaceuticals
• Optimizing Market Access Strategies Under AMNOG: How will Germany's Healthcare Reform Impact Global Pricing and Reimbursement Strategies
• Optimizing Strategies for Pharmaceutical Launch Sequencing: A Global Analysis of Shifting Patterns
• Healthcare Expenditure Projections: Understanding Critical Drivers and Their Impact in 36 Key Markets
• Dynamic Pharmaceutical Pricing: What's Really Behind Drug Price Changes?

View all available studies

Benefits:

• Receive valuable insight based on primary research at a reduced, shared cost
• Evaluate market opportunities and risks
• Monitor competitors and customers
• Make informed decisions
• Assess the impact of a changing regulatory environment
• Plan and forecast budgets
• Stay up to date with recent industry developments and market trends

Our studies feature:

• Unique individual reports based on primary research conducted by industry consultants
• Over 50 interviews conducted by local consultants with healthcare stakeholders from each country
• Full customization, allowing clients to validate and modify interview guidelines to accommodate specific business needs
• A tailor-made methodology adapted to deliverables of each project, using
  • Interviews and surveys
  • Consumer surveys
  • Panels

Deliverables

• An electronic report detailing the methodology of our research and results of our in-depth studies and interviews
• Comparative analysis presented in Microsoft PowerPoint® (approximately 50 slides)
• Detailed country profiles for each survey delivered in Microsoft Word® (approximately 20-30 pages)

Our latest studies:

• The New REAlity of Relative Effectiveness: An International Comparison of Evolving Requirements (Available 2012).
  • Developing clinical trial data necessary for reimbursement dossiers is a costly process, and the information needs of regulators, reimbursement authorities, and payers are often very different. This leaves pharmaceutical companies unclear on what are the best types of data to develop in order to secure reimbursement across multiple markets.
  • This study explores the types of data payers are willing to consider to approve and set reimbursement levels for a given drug.
  • Download brochure
• Optimizing Medical Device & Diagnostic Launches: A Country Specific Analysis.
  • This study provides a clear view of the market access and reimbursement landscapes for medical devices and diagnostics in Canada, Australia, Japan, the EU top 5 and the United States.
  • Download brochure
• A 2011 Survey of the European Hospital Drug Market
  • A detailed view of the current state of the hospital drug market in 12 European countries: Belgium, Czech Republic, France, Germany, Italy, Netherlands, Poland, Portugal, Spain, Sweden, Switzerland and the United Kingdom.
  • Download brochure
• Payer - Industry Partnerships: Best Practices for Successful Market Access of New Pharmaceuticals
  • This study will explore the types of payer-industry strategic partnerships that are emerging, as well as the best practices for establishing such partnerships and critical success factors pharmaceutical companies should consider.
  • Download brochure
• Optimizing Market Access Strategies Under AMNOG: How will Germany's Healthcare Reform Impact Global Pricing and Reimbursement Strategies
  • In this new study we will take a detailed look at German healthcare reform and what it really means for the global pharmaceutical industry.
  • Download brochure
• Optimizing Strategies for Pharmaceutical Launch Sequencing: A Global Analysis of Shifting Patterns
  • How cross-market dynamics impact specific product launch sequencing strategies within 20 of the world’s largest markets. Gain the critical insight you need to develop an informed launch sequence strategy that maximizes revenues.
  • Download brochure
• Dynamic Pharmaceutical Pricing: What's Really Behind Drug Price Changes?
  • Understand the drivers of drug prices in 18 countries and 13 major therapeutic areas, so you can develop more informed budgets and go-to-market strategies.
  • Download brochure
• Maximizing Opportunities in the BRIC-MT Bloc: Market Access Strategies in the World's Fastest Growing Markets
  • We explore the opportunities presented by the BRIC-MT Bloc and delve into their regulatory environments.
  • Download brochure
• Business Opportunities in the Private Healthcare Sector
  • We explore the alliances that pharma companies and private healthcare insurers could form to widen the range of products covered, attract new clients and boost sales of products lacking government funding.
  • Download brochure
• Orphan and Ultra-orphan Drugs: Attaching Value to Treatments for Rare Diseases
  • A look at the opportunities orphan drugs present to pharma and biotech companies. We examine regulatory incentives, emerging competition and the value of orphan drugs for certain countries.
  • Download brochure

Also available:

• Biosimilars in Europe and the United States
• Risk-Sharing Agreements: An Alternative Approach to Pricing Negotiations
• Theranostics: Insight into a New Medical Model
• Direct-to-Pharmacy Distribution: Managing Relationships in 12 European Markets
• A Survey of the European Hospital Drug Market
• European Policies for Medicine: Successfully Developing Pharmaceuticals in 15 European Markets

What topics would you like us to cover in the future?

We are always very keen to hear your feedback and suggestions of topics you would like us to cover in future studies. Please send all your suggestions here.

Our expert team provides an independent, fact-based view of the healthcare and pharmaceutical industry, fully supported by our 325+ economists and analysts worldwide with expertise in over 120 industries and 200 countries.

IHS Global Insight is the world leader in economic and financial analysis, forecasting and market intelligence—with more than 40 years experience and an outstanding record for accuracy.